Articles From: - MorphoSys and Xencor Publish Final Results from Phase 1/2a Trial of MOR208 (XmAb5574) in CLL/SLL at ASH Annual Meeting to - VIVINT SOLAR SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Vivint Solar, Inc. -- VSLR


Martinsried / Munich, Germany, Dec.
Sign-up for - MorphoSys and Xencor Publish Final Results from Phase 1/2a Trial of MOR208 (XmAb5574) in CLL/SLL at ASH Annual Meeting investment picks
2014/12/7
More than 200 UnitedHealthcare employees and volunteers from the Fort Lauderdale area joined yesterday to build a new playground at Jack and Jill Children’s Center.
Sign-up for 2014/12/7 - Volunteers Build Playground at Jack and Jill Children’s Center in Fort Lauderdale investment picks
By Wallace Witkowski, MarketWatch SAN FRANCISCO (MarketWatch) -- With gas prices at multiyear lows and consumer sentiment at multiyear highs, retail sales data will likely be the main catalyst for stocks this week.
Sign-up for - UPDATE: Retail sales data to confirm tone of holiday shopping investment picks
Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced the presentation of preliminary data from the luspatercept phase 2 clinical trial in patients with beta-thalassemia at the 56 th American Society of Hematology (ASH) Annual Meeting and Exposition.
Sign-up for - New Data from Luspatercept Phase 2 Clinical Trial in Beta-Thalassemia Presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition investment picks
2014/12/7
Seven-fold lower incidence of VTE in patients treated with ISIS-FXI Rx compared with enoxaparin Data published in New England Journal of Medicine and featured at the American Society of Hematology annual meeting Isis to host a webcast at 9:00 a.m. ET on Monday, December 8, 2014 CARLSBAD, Calif.
Sign-up for 2014/12/7 - Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx for the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery investment picks
-Profile Supports Potential Role in Modulating Tumor Microenvironment in Blood-Related Cancers, Including AML, MDS, CMML and CLL- -Analysis Also Provides Scientific Basis for Pacritinib's Lack of Myelosuppression, a Unique Attribute Among Agents in Development for Myelofibrosis- SEATTLE , Dec.
Sign-up for - CTI BioPharma Announces Comprehensive Kinome Analysis that Demonstrates Pacritinib Inhibits Kinases Linked to a Spectrum of Blood-Related Cancers investment picks
http://media.marketwire.com/attachments/201211/99925_41732_threshold.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1163477&ProfileId=051205&sourceType=1 SAN FRANCISCO, CA --
Sign-up for - Encouraging Initial Data From Ongoing Phase 1/2 Trial of TH-302 Plus Bortezomib (Velcade(R)) Plus Dexamethasone ("TBorD") in Patients With Relapsed/Refractory Multiple Myeloma Presented at ASH Annual Meeting investment picks
2014/12/6
By Catey Hill, MarketWatch Last year, more than 11 million toys were recalled, according to the public interest nonprofit group U.S. PIRG Education Fund -- many because they posed a danger to children.
Sign-up for 2014/12/6 - UPDATE: 8 popular, but potentially dangerous, toys for kids investment picks
2014/12/6
- Note: This press release corresponds to abstract 31.
Sign-up for 2014/12/6 - IMBRUVICA® (ibrutinib) Data Suggests Promise in Multiple Myeloma investment picks
Bristol-Myers Squibb Company (NYSE:BMY) today announced positive results from a cohort of patients in its ongoing Phase 1b trial (CheckMate -039) which evaluated PD-1 immune checkpoint inhibitor, Opdivo (nivolumab), in patients with relapsed or refractory hematological malignancies (n=23). Results showed high levels of response in patients with relapsed or refractory classical Hodgkin Lymphoma (HL), with an overall response rate of 87% (n=20) and stable disease in 13% (n=3). These findings were published today in The New England Journal of Medicine ( NEJM ) and highlighted in the press briefing on Saturday, December 6 during the 56 th annual meeting of the American Society for Hematology (Abstract #289). In patients with HL, initial treatment typically consists of chemotherapy and/or radiation therapy, followed by an autologous stem cell
Sign-up for - Opdivo (nivolumab) Demonstrates High Overall Response Rate of 87% for Treatment of Relapsed or Refractory Hodgkin Lymphoma investment picks
93% (13/14) of evaluable CLL patients treated at dose levels ≥ 800mg of original formulation or any dose of the micronized formulation achieved a > 50% reduction in nodal size (a nodal PR) and 50% (7/14) achieved a partial response per iwCLL (Hallek 2008) criteria 100% (6/6) of CLL and iNHL patients achieving TGR-1202 drug concentrations above 4,000ng/ml responded at the first or second efficacy assessment with at least a nodal PR for CLL or PR for iNHL; Expansion cohorts now open at 800mg QD for CLL and 1200mg QD for iNHL, the dose level that appears to provide patients (3/3) with drug concentrations > 4,000ng/ml No drug related hepatic toxicity or colitis observed with 55 patients treated to date and median time on study of approximately 6 months and some patients on study for over 1.5 years TGR-1202 has been well-tolerated with no dose-related trends in adverse events observed and no MTD reached to date, dose escalation continues now at 1800mg QD SAN
Sign-up for - Interim Data From Phase 1 Dose Escalation Clinical Trial of TGR-1202, the Once-Daily PI3K Delta Inhibitor, Demonstrates Significant Clinical Activity and Lack of Hepatic Toxicity in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma investment picks
2014/12/6
-Catey Hill; 415-439-6400; AskNewswires@dowjones.com 6.
Sign-up for 2014/12/6 - UPDATE: 10 things grocery stores won't tell you -2- investment picks
Seattle Genetics, Inc. (Nasdaq: SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502) today reported data demonstrating that Hodgkin lymphoma (HL) patients at risk of relapse following an autologous stem cell transplant (ASCT) who received ADCETRIS (brentuximab vedotin) as consolidation therapy immediately after ASCT had significant improvement in progression-free survival (PFS) compared to patients who received placebo (median of 43 months versus 24 months, respectively; hazard ratio=0.57; p-value=0.001). The data from the AETHERA trial were featured at the 56th American Society of Hematology (ASH) Annual Meeting press program today and will be presented in an oral session on December 8, 2014.
Sign-up for - Seattle Genetics and Takeda Report Phase 3 AETHERA Clinical Trial Data from ADCETRIS® (Brentuximab Vedotin) in Post-Transplant Hodgkin Lymphoma Patients at Risk of Relapse at ASH Annual Meeting investment picks
2014/12/6
By Amy Hoak, MarketWatch 'Smart home' gadgets become more affordable and more common Homeowners are increasingly looking to technology for home security solutions, to save on heating and cooling costs and even to help them cook the perfect steak.
Sign-up for 2014/12/6 - UPDATE: 5 tech gadgets you need in your home today investment picks
2014/12/6
Chipotle's Arnold says the chain has "a culture where employees are trained to make what they can with the ingredients we have if a customer asks." In other words, go ahead and enjoy your Quesarito.
Sign-up for 2014/12/6 - UPDATE: 10 things Chipotle won't tell you -2- investment picks
Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today early study findings demonstrating that KEYTRUDA ® (pembrolizumab), the company’s anti-PD-1 therapy, achieved an overall response rate of 66 percent, as assessed by International Harmonization Project response criteria (n=19/29: 95% CI, 46-82), in transplant-ineligible and failure patients with relapsed/refractory classical Hodgkin Lymphoma (cHL) whose disease progressed on or after treatment with brentuximab vedotin.
Sign-up for - Data Investigating KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, in Patients with Classical Hodgkin Lymphoma Presented at ASH Annual Meeting investment picks
78 Percent of Patients Treated With BLINCYTO Experienced a Complete Minimal Residual Disease (MRD) Response After One Treatment Cycle Results to be Presented During an Oral Session at the American Society of Hematology (ASH) 56th Annual Meeting and Exposition on Monday, December 8 at 10:30 a.m. PT Data to be Featured in ASH Press Briefing on Saturday, December 6 at 10 a.m. PT THOUSAND OAKS, Calif.
Sign-up for - Amgen Announces New Data From Phase 2 BLINCYTO™ (blinatumomab) Immunotherapy Study In Patients With Acute Lymphoblastic Leukemia And Minimal Residual Disease investment picks
2014/12/6
By Quentin Fottrell, MarketWatch The Material Girl wasn't kidding around.
Sign-up for 2014/12/6 - UPDATE: 10 richest musicians in the world investment picks
2014/12/6
By Charles Passy, MarketWatch 1.
Sign-up for 2014/12/6 - UPDATE: 10 things Chipotle won't tell you investment picks
2014/12/6
The future of 4K Ultra HD received a rocket-propelled boost today with the launch of a DIRECTV satellite that will deliver the new standard in TV image quality directly to viewers’ homes in the U.S., along with more HD for local markets and backup for DIRECTV’s existing fleet of six HD satellites.
Sign-up for 2014/12/6 - 4K Ultra HD Gets a Lift with Successful DIRECTV Satellite Launch investment picks
CBS Corporation (NYSE: CBS.A and CBS) and DISH Network L.L.C., a wholly owned subsidiary of DISH Network Corporation (NASDAQ: DISH), have reached a multi-year agreement for carriage of CBS owned stations across the country, as well as CBS Sports Network, Smithsonian Channel, TVGN and Showtime Networks, which includes Showtime TV Everywhere and Video-on-Demand rights.
Sign-up for - CBS and DISH Reach Content Carriage Agreement investment picks
Seattle Genetics, Inc. (Nasdaq: SGEN) today presented data from two ongoing phase 1 clinical trials evaluating SGN-CD19A, an antibody-drug conjugate (ADC) in development for the treatment of B-cell malignancies, including non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL), at the 56 th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in San Francisco, CA December 6-9, 2014.
Sign-up for - Seattle Genetics Presents Data from SGN-CD19A Antibody-Drug Conjugate at ASH Annual Meeting investment picks
Results Show Durable Responses in High Risk Patient Population MARTINSRIED, Germany , MUNICH and MONROVIA, Calif.
Sign-up for - MorphoSys and Xencor Publish Final Results from Phase 1/2a Trial of MOR208 (XmAb5574) in CLL/SLL at ASH Annual Meeting investment picks
CBS Corp (CBS) and Dish Network (DISH) reached an multi-year agreement on Saturday, ending a dispute that led to a short programming blackout on Friday night.
Sign-up for - CBS and Dish settle fee dispute investment picks
2014/12/6
UnitedHealthcare and the 4-H Youth Development Program at the University of Florida are expanding a successful partnership called Eat4-Health that helps tackle obesity by promoting healthy eating and active lifestyles among youth and families.
Sign-up for 2014/12/6 - Florida 4-H and UnitedHealthcare Expand “Eat4-Health” Partnership, Use “Pedal Power” to Help Tackle Obesity and Encourage Healthy Lifestyles Among Youth investment picks
2014/12/6
By Catey Hill, MarketWatch On special today: Old produce, big markups and hygiene problems 1.
Sign-up for 2014/12/6 - UPDATE: 10 things grocery stores won't tell you investment picks
Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: - MorphoSys and Xencor Publish Final Results from Phase 1/2a Trial of MOR208 (XmAb5574) in CLL/SLL at ASH Annual Meeting to - VIVINT SOLAR SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Vivint Solar, Inc. -- VSLR
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent